Ajou University Industry-Academic Cooperation Foundation

Standigm Inc

Yu Ree Choi

Sang Myun Park

Jae Bong Kim

Jin Han Kim

Hee Jung Koo

So Jeong Yun

Sang Ok Song

Soo Jin Park

Soo Jeong Kim

Min Young So

A composition for preventing or treating synucleinopathies, which includes efavirenz or a salt or solvate thereof and a pharmaceutically acceptable carrier, is provided. The composition is useful in preventing or treating synucleinopathies, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, because the composition serves to hinder cell-to-cell transmission of alpha-synuclein, prevent intracellular aggregation of α-synuclein, and inhibit transmission of aggregated α-synuclein.

Composition for treating synucleinopathies

A composition including a substance that inhibits an expression or activity of c-src and its use in inhibiting aggregation and/or migration of α-syn are disclosed. The composition may be a pharmaceutical composition and can be used for preventing or treating synucleinopathy. The substance can inhibit the signal transduction induced by α-syn migrating to adjacent cells, thus mitigating the cytotoxic influence of α-syn on the adjacent cells; and can inhibit the denaturation of monomeric α-syn into aggregated α-syn, which may be a major cause of synucleinopathy, and thus, can be beneficially used as a therapeutic agent for synucleinopathy.

Pharmaceutical composition comprising expression or activity inhibitor of c-src for preventing or treating synucleinopathy

This invention provides a method of treating a neurodegenerative disease selected from the group consisting of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, comprising administering a pharmaceutically effective amount of an agent capable of suppressing expression or activity of SHP-1/-2 (Src homology region 2 domain-containing phosphatase-1/-2) or Fc&#x3b3;RIIB (IgG Fc receptor II-B) to a subject having the neurodegenerative disease, wherein the agent capable of suppressing expression of SHP-1/-2 or Fc&#x3b3;RIIB is selected from the group consisting of miRNA, siRNA, shRNA, antisense oligonucleotide, and a combination thereof capable of specifically binding to mRNA of SHP-1/-2 or Fc&#x3b3;RIIB, and the agent capable of suppressing activity of SHP-1/-2 or Fc&#x3b3;RIIB is selected from the group consisting of an antibody, an aptamer, an antagonist, and a combination thereof capable of specifically binding to a protein of SHP-1/-2 or Fc&#x3b3;RIIB.

Pharmaceutical composition for preventing or treating neurodegenerative diseases

Growing community of inventors

Suwon-si, South Korea

Yu Ree Choi